Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMA/CNBC’s MEDICAL TV PROGRAMMING: PHYSICIAN AND CONSUMER FIVE-HOUR BLOCKS

Executive Summary

AMA/CNBC's MEDICAL TV PROGRAMMING: PHYSICIAN AND CONSUMER FIVE-HOUR BLOCKS will air beginning Feb. 29 under a partnership between the American Medical Association and the CNBC cable network announced Jan. 15. The programs will provide physician- oriented programs from 10 a.m. to 1 p.m. on Saturdays followed by consumer-directed medical programs for the next two hours. The same five-hour block will be repeated from 10-3 on Sundays. CNBC broadcasts to 45 mil. cable subscribers in North America. Another partner in the CNBC deal is Art Ulene, MD, who currently hosts AMA's consumer-oriented show "Living Well America" and previously provided medical reports to NBC's "Today Show" and ABC's "Home Show". The fourth partner is Orbis Broadcast Group, a Chicago-based production company focusing on medical programs. The venture with CNBC will replace AMA's current arrangement with the Discovery cable channel for three hours weekly of both professional and consumer medical programming. AMA plans to continue the same programming and advertising policies it has used on the Discovery channel to ensure that the broadcasts meet the standards of FDA and other groups for industry promotional activities and clinical presentations. For example, no direct-to-consumer ads of prescription products are permitted. The physician-oriented shows, many of which qualify for continuing medical education credits, will be maintained as an isolated block of consecutive programs. They will be preceded by a disclaimer that they are intended for medical professionals. Pharmaceutical ads will be accompanied by a visual and audio scroll providing the "brief summary" of labeling plus an "800" number to telephone for additional information. AMA's programming on the Discovery channel included advertising by more than 30 pharmaceutical, medical device and medical product packaging companies. AMA cited two reasons for its switch to the CNBC network -- a desire to expand the number of broadcast hours and an interest to add more news-oriented programming. CNBC provides primarily news broadcasts with a focus on business and financial issues. For the physician program block, for example, AMA is developing a show entitled "Direct from the Hill" that will provide news on federal regulatory and legislative activities. AMA plans to invite officials from FDA and other agencies to appear on the show to provide updates on agency policies -- similar to the Journal of the American Medical Association articles reviewing agency activities that FDA officials now author but broadcast on a more timely basis. Many of AMA's current programs on Discovery -- such as "Medical Rounds," "Journal Scan," and "AMA Video Clinic" -- will be continued on CNBC.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS020271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel